drugset / Trial / NCT02633137
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effects, good and/or bad, the treatment including 1) Lenalidomide-RCHOP, 2) R-HIDAC, and 3) Lenalidomide-Rituximab maintenance has on the participant and their lymphoma.
Timeline
- Start
- 2015-12-14
- Primary completion
- 2023-11-07
- Completion
- 2023-11-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 1 g | — |
| Subject | Cytarabine | Small molecule | 2 g | — |
| Subject | Cytarabine | Small molecule | 3 g | — |
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | Intravenous |
| Subject | Lenalidomide | Other / unclassified | 15 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |